TABLE 2.

Distribution of demographic and biological features between CEBPA^POS and CEBPA^NEG patients.

	CEBPAPOS N = 10		CEBPANEG N = 70		p
Sex	aN	%	N	%
Female	4	40	32	45.7
Male	6	60	38	54.3
Mean age at bDx	Years	Range	Years	Range
Female	9.24	4.9 - 10.1	9.4	0.4 - 17.5
Male	9.7	5.3 - 15.9	9.1	1.3 - 16.6
Total	9.6	4.9 - 15.9	9.3	0.4 - 17.5
Mean cBM blast at Dx	Mean (%)	Range	Mean (%)	Range
	84.3	65 - 98	75.9	23 - 100
dWBC count at Dx/mm3	N	%	N	%
<11,000	2	20	29	41.4
11,000–100,000	3	30	32	45.7
>100,000	5	50	9	12.9	0.004
dWBC median at Dx/mm3	N	Median mm3	N	Median mm3
<11,000	2	5000	29	4300
11,000–100,000	3	42400	32	34450
>100,000	5	249000	9	146100
Total	10	117630	70	18830
Mean overall survival	N	Years	N	Years
OS	10	0.9	69	1.97
OS ≤ 1 year	5 (50%)	0.3	25 (36.2%)	0.35
OS > 1 year	5 (50%)	1.8	44 (63.8%)	3.1	0.0001
OS ≤ 2 year	8 (80%)	0.8	40 (58%)	0.8
OS > 2 year	2 (20%)	2.1	29 (42%)	3.9	0.0258
eFAB subtypes	N	%	N	%
M0	0	0	1	1.4
M1	1	10	8	11.4
M2	7	70	20	28.6	0.009
M3	2	20	27	38.6
M4	0	0	12	17.1
M5	0	0	1	1.4
M6	0	0	1	1.4
Treatment protocols	N	%	N	%
fBFM-1998	4	40	21	30
BFM-2001	2	20	4	5.7
gNOPHO-AML93	2	20	18	25.7
hPETHEMA-APL-05	2	20	27	38.6
Risk classification at Dx.	N	%	N	%
Standard	0	0	6	8.6
Intermediate	0	0	4	5.7
High	5	50	39	55.7
Not classified	5	50	21	30
Achievement of iCR	N	%	N	%
	10	100	67	95.7
Relapsed	N	%	N	%
	3	30	4	5.7%

^aN, number of patients; ^bDx, diagnosis; ^cBM, bone marrow; ^dWBC, white blood cell; ^eFAB, French-American-British classification; ^fBFM, Berlin-Frankfurt-Münster; ^gNOPHO, Nordic Society of Pediatric Hematology and Oncology; ^hPETHEMA, Spanish Program of Treatments in Hematology; ⁱCR, complete remission assessed on day 28. P value < 0.05 was considered statistically significant.